CompletedNot Applicable

Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT)

United States1 participantsStarted 2013-01-24

Plain-language summary

Background: * High density lipoprotein (HDL), or good cholesterol, moves cholesterol from the artery walls back to the liver. A blood enzyme known as LCAT maintains HDL levels and helps it remove cholesterol from the body. Familial LCAT deficiency (FLD) is a genetic disease that results in low levels or total absence of LCAT. People with FLD often have kidney problems, and may develop kidney failure. Researchers think that the clinical problems of FLD can be prevented or even reversed by replacing the defective enzyme. * There are no drugs that increase LCAT. It has to be artificially made and infused into the body. The artificial LCAT is called recombinant human LCAT, or ACP-501. Researchers want to see how well it works in one person with FLD and poor kidney function. Objectives: \- To see whether ACP-501 can improve the symptoms of FLD. Eligibility: \- One person (the study participant) with FLD. Design: * The participant will be screened with a physical exam and medical history. Blood samples will be collected. * The participant will receive ACP-501 and remain in the hospital for 24 hours for regular blood tests. The participant may stay in the hospital or return for daily clinic visits until it is time for the next dose. The second dose will be given on Day 4 or Day 8. * If an optimal dose has not yet been identified, a third dose will be given 7 days after the second dose. * The participant will then go home, but must return to the hospital for ACP-501 infusions and blood tests every 1 or 2 weeks, as needed. Every 3 months, the participant will have a full clinic visit with blood tests and other studies.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

* INCLUSION CRITERIA: Subject must meet all of the following inclusion criteria to be eligible for enrollment into the study: * Greater than or equal to 18 years at screening; * Confirmed FLD diagnosis through genotype confirmation of a LCAT mutation, as documented at screening or from previous testing; * History of HDL-C \< 15 mg/dL over the past year; * Serum creatinine \> 3 mg/dL; * Increasing renal dysfunction resulting in ESRD; * Chronic concomitant medications must be stable for at least 2 weeks prior to screening (for example, lipid-altering drugs and/or ACE-inhibitors used for the treatment of FLD). * Subject is willing and able to comply with scheduled study visits and is able to tolerate study procedures, including weekly to bi-weekly infusions over 1 year. * Subject must be able to provide a personally-signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. * Subject may be currently on dialysis or require dialysis during the study EXCLUSION CRITERIA: Subject will not be included in the study if he presents with any of the following: * History of febrile illness within 5 days prior to dosing; * Active non-basal cell cutaneous malignancy requiring surgery, chemotherapy, and/or radiation in the past 12 months. NOTE: Subjects with localized prostate cancer under a watchful-waiting treatment plan without evidence of disease progression in the past year may participate in the study if approved…

What they're measuring

HDL

Timeframe: weekly

Trial details

NCT IDNCT04737720

SponsorNational Heart, Lung, and Blood Institute (NHLBI)

Sponsor typeNIH

Study typeOBSERVATIONAL

Primary completion2013-12-12